Effectiveness of estrogen and its derivatives over dexamethasone in the treatment of COVID-19
Authors:
- Darakhshan ParveenDPDarakhshan Parveen
- Anwesha DasADAnwesha Das
- Shaista AminSAShaista Amin
- M. Mumtaz AlamMAM. Mumtaz Alam
- Mymoona AkhterMAMymoona Akhter
- Mohammad Ahmed KhanMKMohammad Ahmed Khan
- Ruhi AliRARuhi Ali
- Tarique AnwerTATarique Anwer
- Khursheed A. SheikhKSKhursheed A. Sheikh
- Faizul AzamFaizul Azam
- M. ShaquiquzzamanMSM. Shaquiquzzaman
- 2 May 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (4) , 1858-1874
Abstract
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus and dexamethasone is a glucocorticoid widely used for its treatment. Dexamethasone is not used in non-severe cases due to its immunosuppressant action. So, considering this, Estrogen and Estetrol were tested for the treatment of COVID-19 as they all possess a common steroid ring and dislike dexamethasone, they are immunoenhancer. Virtual screening of test ligands was performed through molecular docking, MM-GBSA, simulations, in silico ADMET and drug-likeness prediction to identify their potential to inhibit the effects of SARS-CoV-2. Results showed that test ligands possess drug-like properties and they are safe as drug candidates. The protein-ligand interaction study revealed that they bind with the amino acid residues at the active site of the target proteins and the test ligands possess better binding potential than Dexamethasone. With protein Mpro, Estetrol and Estrogen showed docking score of −7.240 and −5.491 kcal/mol, and with protein ACE2, Estetrol and Estrogen showed docking score of −5.269 and −4.732 kcal/mol, respectively. Further, MD Simulation was carried out and most of the interactions of molecular docking are preserved during simulation. The prominent interactions that our test ligands showed during MD Simulation are similar to drugs that possess in vitro anticovid activity as shown in recent studies. Hence, our test ligands possessed potential for anticovid activity and they should be further tested through in vitro and in vivo studies for their activity against COVID-19. Communicated by Ramaswamy H. SarmaKeywords
Funding Information
- Jamia Hamdard, DST FIST (SR/FST/LS-I/2018/151)
This publication has 54 references indexed in Scilit:
- Estrogen synthesis and signaling pathways during aging: from periphery to brainTrends in Molecular Medicine, 2013
- The Interplay between Estrogen and Fetal Adrenal CortexJournal of Nutrition and Metabolism, 2012
- Quantifying the chemical beauty of drugsNature Chemistry, 2012
- Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributionsJournal of Cheminformatics, 2009
- Identifying and Characterizing Binding Sites and Assessing DruggabilityJournal of Chemical Information and Modeling, 2009
- Effect of Drug Lipophilicity and Ionization on Permeability Across the Buccal Mucosa: A Technical NoteAAPS PharmSciTech, 2008
- Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis modelClimacteric, 2008
- Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand ComplexesJournal of Medicinal Chemistry, 2006
- Estrogen receptors and human diseaseJournal of Clinical Investigation, 2006
- A hierarchical approach to all‐atom protein loop predictionProteins: Structure, Function, and Bioinformatics, 2004